These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 30779858)
1. Fra1 Controls Rheumatoid Factor Autoantibody Production by Bone Marrow Plasma Cells and the Development of Autoimmune Bone Loss. Grötsch B; Lux A; Rombouts Y; Hoffmann AC; Andreev D; Nimmerjahn F; Xiang W; Scherer HU; Schett G; Bozec A J Bone Miner Res; 2019 Jul; 34(7):1352-1365. PubMed ID: 30779858 [TBL] [Abstract][Full Text] [Related]
2. How Autoantibodies Regulate Osteoclast Induced Bone Loss in Rheumatoid Arthritis. Steffen U; Schett G; Bozec A Front Immunol; 2019; 10():1483. PubMed ID: 31333647 [TBL] [Abstract][Full Text] [Related]
3. Immunoglobulin G complexes without sialic acids enhance osteoclastogenesis but do not affect arthritis-mediated bone loss. Sehic E; Westerlund A; Lagerquist MK; Lerner UH; Carlsten H; Henning P; Engdahl C Scand J Immunol; 2021 May; 93(5):e13009. PubMed ID: 33320370 [TBL] [Abstract][Full Text] [Related]
4. Role of heterodimerization of c-Fos and Fra1 proteins in osteoclast differentiation. Bakiri L; Takada Y; Radolf M; Eferl R; Yaniv M; Wagner EF; Matsuo K Bone; 2007 Apr; 40(4):867-75. PubMed ID: 17189721 [TBL] [Abstract][Full Text] [Related]
5. Immune complex-induced inhibition of osteoclastogenesis is mediated via activating but not inhibitory Fcγ receptors on myeloid precursor cells. Grevers LC; de Vries TJ; Everts V; Verbeek JS; van den Berg WB; van Lent PL Ann Rheum Dis; 2013 Feb; 72(2):278-85. PubMed ID: 22918932 [TBL] [Abstract][Full Text] [Related]
6. Inflammatory monocytes and Fcγ receptor IV on osteoclasts are critical for bone destruction during inflammatory arthritis in mice. Seeling M; Hillenhoff U; David JP; Schett G; Tuckermann J; Lux A; Nimmerjahn F Proc Natl Acad Sci U S A; 2013 Jun; 110(26):10729-34. PubMed ID: 23754379 [TBL] [Abstract][Full Text] [Related]
7. Fas/S1P Hutami IR; Izawa T; Mino-Oka A; Shinohara T; Mori H; Iwasa A; Tanaka E Biochem Biophys Res Commun; 2017 Sep; 490(4):1274-1281. PubMed ID: 28687489 [TBL] [Abstract][Full Text] [Related]
8. The AP-1 transcription factor Fra1 inhibits follicular B cell differentiation into plasma cells. Grötsch B; Brachs S; Lang C; Luther J; Derer A; Schlötzer-Schrehardt U; Bozec A; Fillatreau S; Berberich I; Hobeika E; Reth M; Wagner EF; Schett G; Mielenz D; David JP J Exp Med; 2014 Oct; 211(11):2199-212. PubMed ID: 25288397 [TBL] [Abstract][Full Text] [Related]
9. Induction of IgG rheumatoid factor (RF) production by antibody-antibody (RF-like) immune complexes: the role of T cells, complement and Fc gamma receptors. Nordström E; Möller E; Abedi-Valugerdi M J Autoimmun; 1998 Apr; 11(2):131-40. PubMed ID: 9650092 [TBL] [Abstract][Full Text] [Related]
10. Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss. Harre U; Lang SC; Pfeifle R; Rombouts Y; Frühbeißer S; Amara K; Bang H; Lux A; Koeleman CA; Baum W; Dietel K; Gröhn F; Malmström V; Klareskog L; Krönke G; Kocijan R; Nimmerjahn F; Toes RE; Herrmann M; Scherer HU; Schett G Nat Commun; 2015 Mar; 6():6651. PubMed ID: 25825024 [TBL] [Abstract][Full Text] [Related]
11. Desoxyrhapontigenin inhibits RANKL‑induced osteoclast formation and prevents inflammation‑mediated bone loss. Tran PT; Park DH; Kim O; Kwon SH; Min BS; Lee JH Int J Mol Med; 2018 Jul; 42(1):569-578. PubMed ID: 29693149 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of osteoclast differentiation and collagen antibody-induced arthritis by CTHRC1. Jin YR; Stohn JP; Wang Q; Nagano K; Baron R; Bouxsein ML; Rosen CJ; Adarichev VA; Lindner V Bone; 2017 Apr; 97():153-167. PubMed ID: 28115279 [TBL] [Abstract][Full Text] [Related]
13. Autoimmunity as a trigger for structural bone damage in rheumatoid arthritis. Schett G Mod Rheumatol; 2017 Mar; 27(2):193-197. PubMed ID: 28051887 [TBL] [Abstract][Full Text] [Related]
14. Siglec-15 is a potential therapeutic target for postmenopausal osteoporosis. Kameda Y; Takahata M; Mikuni S; Shimizu T; Hamano H; Angata T; Hatakeyama S; Kinjo M; Iwasaki N Bone; 2015 Feb; 71():217-26. PubMed ID: 25460183 [TBL] [Abstract][Full Text] [Related]
15. Effects of interleukin-7/interleukin-7 receptor on RANKL-mediated osteoclast differentiation and ovariectomy-induced bone loss by regulating c-Fos/c-Jun pathway. Zhao JJ; Wu ZF; Yu YH; Wang L; Cheng L J Cell Physiol; 2018 Sep; 233(9):7182-7194. PubMed ID: 29663382 [TBL] [Abstract][Full Text] [Related]
17. A novel small molecule, NecroX-7, inhibits osteoclast differentiation by suppressing NF-κB activity and c-Fos expression. Kim HJ; Yoon KA; Lee MK; Kim SH; Lee IK; Kim SY Life Sci; 2012 Nov; 91(19-20):928-34. PubMed ID: 23000100 [TBL] [Abstract][Full Text] [Related]
18. The tyrosine kinase inhibitor GNF-2 suppresses osteoclast formation and activity. Kim HJ; Yoon HJ; Choi JY; Lee IK; Kim SY J Leukoc Biol; 2014 Feb; 95(2):337-45. PubMed ID: 24130113 [TBL] [Abstract][Full Text] [Related]
19. Poligoni Multiflori Radix enhances osteoblast formation and reduces osteoclast differentiation. Han SY; Lee KH; Kim YK Int J Mol Med; 2018 Jul; 42(1):331-345. PubMed ID: 29620250 [TBL] [Abstract][Full Text] [Related]
20. Inflammatory activation of the FcγR and IFNγR pathways co-influences the differentiation and activity of osteoclasts. Groetsch B; Schachtschabel E; Tripal P; Schmid B; Smith AS; Schett G; Bozec A Front Immunol; 2022; 13():958974. PubMed ID: 36148242 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]